Comparative analysis of MitraClip/TriClip and PASCAL in transcatheter tricuspid valve repair for tricuspid regurgitation: a systematic review and meta-analysis.
Tricuspid Valve Insufficiency
/ surgery
Humans
Tricuspid Valve
/ surgery
Treatment Outcome
Cardiac Catheterization
/ instrumentation
Heart Valve Prosthesis Implantation
/ instrumentation
Aged
Female
Male
Heart Valve Prosthesis
Recovery of Function
Prosthesis Design
Risk Factors
Middle Aged
Aged, 80 and over
Meta-analysis
MitraClip
Pascal
Transcatheter tricuspid valve repair
TriClip
Tricuspid regurgitation
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
07
08
2023
accepted:
17
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
The edge-to-edge transcatheter tricuspid valve repair (TTVR) has emerged as a promising technique for the treatment of tricuspid regurgitation (TR). Despite its potential, comparative data on the performance of the novel edge-to-edge devices-MitraClip, PASCAL, and TriClip-remain controversial. In this study, we aim to evaluate the safety and efficacy of these devices in treating TR. Five databases were systematically searched up to May 2023, with an updated search conducted in May 2024. Only original studies were included in the analysis and were critically evaluated using an adapted version of the Newcastle-Ottawa Scale (NOS) for observational cohort studies and the Cochrane Risk of Bias (ROB) tool for randomized controlled trials. The database search yielded 2239 studies, out of which 21 studies were included in the final analysis. These studies encompassed a total of 2178 patients who underwent TTVR using either the MitraClip, TriClip, or PASCAL devices. The risk of bias across these studies ranged from moderate to high. No significant differences were found among the three devices in terms of effective regurgitant orifice area (EROA) and tricuspid regurgitant volume. However, TriClip demonstrated statistically superior efficacy in reducing vena contracta compared to both MitraClip and PASCAL (P < 0.01) [TriClip: (MD = -7.4; 95% CI: -9.24, -5.56), MitraClip: (MD = -4.04; 95% CI: -5.03, -3.05), and PASCAL: (MD = -6.56; 95% CI: -7.76, -5.35)]. The procedural success rates and incidence of single leaflet device attachment (SLDA) were similar across all devices. Furthermore, there were no significant differences in mortality, stroke rates, or major bleeding events among the three devices. The TriClip outperforms the MitraClip and PASCAL in reducing vena contracta width, indicating greater effectiveness for severe tricuspid regurgitation. All devices show similar safety profiles and procedural success rates. Further research is needed to confirm these results.
Sections du résumé
BACKGROUND
BACKGROUND
The edge-to-edge transcatheter tricuspid valve repair (TTVR) has emerged as a promising technique for the treatment of tricuspid regurgitation (TR). Despite its potential, comparative data on the performance of the novel edge-to-edge devices-MitraClip, PASCAL, and TriClip-remain controversial. In this study, we aim to evaluate the safety and efficacy of these devices in treating TR.
METHODS
METHODS
Five databases were systematically searched up to May 2023, with an updated search conducted in May 2024. Only original studies were included in the analysis and were critically evaluated using an adapted version of the Newcastle-Ottawa Scale (NOS) for observational cohort studies and the Cochrane Risk of Bias (ROB) tool for randomized controlled trials.
RESULTS
RESULTS
The database search yielded 2239 studies, out of which 21 studies were included in the final analysis. These studies encompassed a total of 2178 patients who underwent TTVR using either the MitraClip, TriClip, or PASCAL devices. The risk of bias across these studies ranged from moderate to high. No significant differences were found among the three devices in terms of effective regurgitant orifice area (EROA) and tricuspid regurgitant volume. However, TriClip demonstrated statistically superior efficacy in reducing vena contracta compared to both MitraClip and PASCAL (P < 0.01) [TriClip: (MD = -7.4; 95% CI: -9.24, -5.56), MitraClip: (MD = -4.04; 95% CI: -5.03, -3.05), and PASCAL: (MD = -6.56; 95% CI: -7.76, -5.35)]. The procedural success rates and incidence of single leaflet device attachment (SLDA) were similar across all devices. Furthermore, there were no significant differences in mortality, stroke rates, or major bleeding events among the three devices.
CONCLUSION
CONCLUSIONS
The TriClip outperforms the MitraClip and PASCAL in reducing vena contracta width, indicating greater effectiveness for severe tricuspid regurgitation. All devices show similar safety profiles and procedural success rates. Further research is needed to confirm these results.
Identifiants
pubmed: 39402473
doi: 10.1186/s12872-024-04201-6
pii: 10.1186/s12872-024-04201-6
doi:
Types de publication
Systematic Review
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
557Informations de copyright
© 2024. The Author(s).
Références
Hahn RT, Tricuspid Regurgitation. N Engl J Med. 2023;388(20):1876–91. https://doi.org/10.1056/NEJMra2216709 .
doi: 10.1056/NEJMra2216709
pubmed: 37195943
Topilsky Y, Maltais S, Medina Inojosa J, et al. Burden of Tricuspid Regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging. 2019;12(3):433–42. https://doi.org/10.1016/j.jcmg.2018.06.014 .
doi: 10.1016/j.jcmg.2018.06.014
pubmed: 30121261
Axtell AL, Bhambhani V, Moonsamy P, et al. Surgery does not improve survival in patients with isolated severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74(6):715–25. https://doi.org/10.1016/j.jacc.2019.04.028 .
doi: 10.1016/j.jacc.2019.04.028
pubmed: 31071413
pmcid: 8890054
Scotti A, Sturla M, Granada JF, et al. Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 patients from 35 studies. EuroIntervention. 2022;18(10):840–51. https://doi.org/10.4244/EIJ-D-22-00442 .
doi: 10.4244/EIJ-D-22-00442
pubmed: 36197445
pmcid: 10167545
Muntané-Carol G, Taramasso M, Miura M, et al. Transcatheter tricuspid valve intervention in patients with right ventricular dysfunction or pulmonary hypertension: insights from the TriValve Registry. Circ Cardiovasc Interv. 2021;14(2):e009685. https://doi.org/10.1161/CIRCINTERVENTIONS.120.009685 .
doi: 10.1161/CIRCINTERVENTIONS.120.009685
pubmed: 33541097
Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388(20):1833–42. https://doi.org/10.1056/NEJMoa2300525 .
doi: 10.1056/NEJMoa2300525
pubmed: 36876753
Nickenig G, Kowalski M, Hausleiter J, et al. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-Edge MitraClip technique. Circulation. 2017;135(19):1802–14. https://doi.org/10.1161/CIRCULATIONAHA.116.024848 .
doi: 10.1161/CIRCULATIONAHA.116.024848
pubmed: 28336788
Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve Intervention: mid-term results from the International TriValve Registry. JACC Cardiovasc Interv. 2019;12(2):155–65. https://doi.org/10.1016/j.jcin.2018.10.022 .
doi: 10.1016/j.jcin.2018.10.022
pubmed: 30594510
Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter Versus Medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74(24):2998–3008. https://doi.org/10.1016/j.jacc.2019.09.028 .
doi: 10.1016/j.jacc.2019.09.028
pubmed: 31568868
Higgins JP, Thomas J, Chandler J et al. Cochrane handbook for systematic reviews of interventions. Second edition. Hoboken, NJ: Wiley-Blackwell; 2020.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71 .
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Fernandez P. Zotero: information management software 2.0. Libr Hi Tech News. 2011;28(4):5–7. https://doi.org/10.1108/07419051111154758 .
doi: 10.1108/07419051111154758
Birkinbine BJ et al. Microsoft Corporation. Global Media Giants. In: Birkinbine, Gómez Herausgeber 2019 – Global Media Giants:383–397.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919 .
doi: 10.1136/bmj.i4919
pubmed: 27733354
pmcid: 5062054
Wells G, Shea B, O’Connell D et al. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. ᅟ. 2000;ᅟ.
Hellhammer K, Schueler R, Eißmann M, et al. Safety of transesophageal echocardiography during transcatheter edge-to-edge tricuspid valve repair: a single-center experience. Front Cardiovasc Med. 2022;9:856028. https://doi.org/10.3389/fcvm.2022.856028 .
doi: 10.3389/fcvm.2022.856028
pubmed: 36304534
pmcid: 9592690
Karam N, Braun D, Mehr M, et al. Impact of transcatheter tricuspid valve repair for severe tricuspid regurgitation on kidney and liver function. JACC Cardiovasc Interv. 2019;12(15):1413–20. https://doi.org/10.1016/j.jcin.2019.04.018 .
doi: 10.1016/j.jcin.2019.04.018
pubmed: 31126888
Sugiura A, Vogelhuber J, Öztürk C, et al. PASCAL versus MitraClip-XTR edge-to-edge device for the treatment of tricuspid regurgitation: a propensity-matched analysis. Clin Res Cardiol. 2021;110(3):451–9. https://doi.org/10.1007/s00392-020-01784-w .
doi: 10.1007/s00392-020-01784-w
pubmed: 33313975
Otto S, Velichkov M, Hamadanchi A, Schulze PC, Moebius-Winkler S. The impact of tricuspid annular geometry on outcome after percutaneous edge-to-edge repair for severe tricuspid regurgitation. Cardiol J. 2021;28(4):579–88. https://doi.org/10.5603/CJ.a2021.0046 .
doi: 10.5603/CJ.a2021.0046
pubmed: 33942279
pmcid: 8277011
Ohno Y, Attizzani GF, Capodanno D, et al. Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. Eur Heart J Cardiovasc Imaging. 2014;15(11):1246–55. https://doi.org/10.1093/ehjci/jeu114 .
doi: 10.1093/ehjci/jeu114
pubmed: 24939944
Mehr M, Taramasso M, Besler C, et al. 1-Year outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation: results from the TriValve Registry. JACC Cardiovasc Interv. 2019;12(15):1451–61. https://doi.org/10.1016/j.jcin.2019.04.019 .
doi: 10.1016/j.jcin.2019.04.019
pubmed: 31395215
Löw K, Orban M, Stocker T, et al. Acute and short-term results of MitraClip XTR vs. PASCAL Transcatheter Valve Repair System for Edge-to-edge repair of severe tricuspid regurgitation. Struct Heart. 2021;5(5):510–7. https://doi.org/10.1080/24748706.2021.1954272 .
doi: 10.1080/24748706.2021.1954272
Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77(4):345–56. https://doi.org/10.1016/j.jacc.2020.11.047 .
doi: 10.1016/j.jacc.2020.11.047
pubmed: 33509390
Mahowald MK, Nishimura RA, Pislaru SV, et al. Reduction in right atrial pressures is Associated with hemodynamic improvements after transcatheter edge-to-edge repair of the tricuspid valve. Circ Cardiovasc Interv. 2021;14(12):e010557. https://doi.org/10.1161/CIRCINTERVENTIONS.121.010557 .
doi: 10.1161/CIRCINTERVENTIONS.121.010557
pubmed: 34814697
Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019;394(10213):2002–11. https://doi.org/10.1016/S0140-6736(19)32600-5 .
doi: 10.1016/S0140-6736(19)32600-5
pubmed: 31708188
Orban M, Besler C, Braun D, et al. Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure. Eur J Heart Fail. 2018;20(6):1055–62. https://doi.org/10.1002/ejhf.1147 .
doi: 10.1002/ejhf.1147
pubmed: 29405554
Ruf TF, Hahn RT, Kreidel F, et al. Short-term clinical outcomes of transcatheter tricuspid valve repair with the Third-Generation MitraClip XTR System. JACC Cardiovasc Interv. 2021;14(11):1231–40. https://doi.org/10.1016/j.jcin.2021.03.033 .
doi: 10.1016/j.jcin.2021.03.033
pubmed: 34112460
Toyama K, Ayabe K, Kar S, et al. Postprocedural changes of Tricuspid Regurgitation after MitraClip Therapy for Mitral Regurgitation. Am J Cardiol. 2017;120(5):857–61. https://doi.org/10.1016/j.amjcard.2017.05.044 .
doi: 10.1016/j.amjcard.2017.05.044
pubmed: 28689751
Kalbacher D, Schäfer U, von Bardeleben RS, et al. Impact of tricuspid valve regurgitation in surgical high-risk patients undergoing MitraClip implantation: results from the TRAMI registry. EuroIntervention. 2017;12(15):e1809–16. https://doi.org/10.4244/EIJ-D-16-00850 .
doi: 10.4244/EIJ-D-16-00850
pubmed: 28089952
Freixa X, Arzamendi D, Del Trigo M, et al. The TriClip system for edge-to-edge transcatheter tricuspid valve repair. A Spanish multicenter study. Rev Esp Cardiol (Engl Ed). 2022;75(10):797–804. https://doi.org/10.1016/j.rec.2022.01.007 .
doi: 10.1016/j.rec.2022.01.007
pubmed: 35288060
Aurich M, Volz MJ, Mereles D, et al. Initial experience with the PASCAL Ace Implant System for treatment of severe tricuspid regurgitation. Circ Cardiovasc Interv. 2021;14(9):e010770. https://doi.org/10.1161/CIRCINTERVENTIONS.121.010770 .
doi: 10.1161/CIRCINTERVENTIONS.121.010770
pubmed: 34433291
Baldus S, Schofer N, Hausleiter J, et al. Transcatheter valve repair of tricuspid regurgitation with the PASCAL system: TriCLASP study 30-day results. Catheter Cardiovasc Interv. 2022;100(7):1291–9. https://doi.org/10.1002/ccd.30450 .
doi: 10.1002/ccd.30450
pubmed: 36378678
Cepas-Guillen PL, La Fuente Mancera JC, Bofarull G. Initial results after the implementation of an Edge-To-Edge transcatheter tricuspid valve repair program. J Clin Med. 2021;10(18). https://doi.org/10.3390/jcm10184252 .
Ali FM, Ong G, Edwards J, Connelly KA, Fam NP. Comparison of transcatheter tricuspid valve repair using the MitraClip NTR and XTR systems. Int J Cardiol. 2021;327:156–62. https://doi.org/10.1016/j.ijcard.2020.11.073 .
doi: 10.1016/j.ijcard.2020.11.073
pubmed: 33301831
Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL Transcatheter Valve Repair System for severe tricuspid regurgitation: a Multicenter, Observational, First-in-human experience. JACC Cardiovasc Interv. 2019;12(24):2488–95. https://doi.org/10.1016/j.jcin.2019.09.046 .
doi: 10.1016/j.jcin.2019.09.046
pubmed: 31857018
Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in Prohibitive Surgical Risk patients. JACC Cardiovasc Interv. 2022;15(24):2523–36. https://doi.org/10.1016/j.jcin.2022.09.005 .
doi: 10.1016/j.jcin.2022.09.005
pubmed: 36121247
Ives CW, Prejean SP, Vardas PN, von Mering G, Ahmed MI. Initial experiences with the MitraClip G4: review of the Novel device features. Innovations (Phila). 2021;16(5):448–55. https://doi.org/10.1177/15569845211030862 .
doi: 10.1177/15569845211030862
pubmed: 34420410
Chakravarty T, Makar M, Patel D, et al. Transcatheter edge-to-edge mitral valve repair with the MitraClip G4 System. JACC Cardiovasc Interv. 2020;13(20):2402–14. https://doi.org/10.1016/j.jcin.2020.06.053 .
doi: 10.1016/j.jcin.2020.06.053
pubmed: 33011141
Lurz P, von Stephan R, Weber M, et al. Transcatheter edge-to-edge repair for treatment of Tricuspid Regurgitation. J Am Coll Cardiol. 2021;77(3):229–39. https://doi.org/10.1016/j.jacc.2020.11.038 .
doi: 10.1016/j.jacc.2020.11.038
pubmed: 33478646